More than just a vial...
New technologies allow scientists to measure thousands of proteins
from a vial of blood.
...powerful health insights
Proteins Express Health
More than just a vial...
New technologies allow scientists to measure thousands of proteins
from a vial of blood.
...powerful health insights
We leverage health prediction algorithms across healthcare ecosystem
Eddie Adams, Ph.D.
Chief Product & Scientific Officer
Led liquid biopsy diagnostic development efforts at Micronoma, Inc., epigenetic product and service development at Active Motif, sample preparation product development at MO BIO Laboratories (acquired by Qiagen). Prior Director of Molecular Diagnostics at NanoMR. Inventor on numerous issued and pending patents in diagnostics, epigenetics, sample preparation and nanotechnology. B.S. in Biotechnology from Rochester Institute of Technology. Ph.D. in Biological Chemistry from Massachusetts Institute of Technology.
Nicola Jessen
Head of Marketing
Leads our Marketing efforts. Previously Head of Company Digitalization & Automation at Siemens Healthineers for Central Eastern Europe and Central Asia. Multiple global roles in strategy, M&A, digital transformation, change management, and product development. Several years of experience as Head of Marketing at a German startup.
Travis Read
Head of Business Development
Leads all deal related activities and externalization efforts for the Company. Previous roles include senior positions in private equity and private equity backed biopharmaceutical companies including Gurnet Point Capital, Coherus Biosciences and M8 Pharmaceuticals. B.A., University of California, Berkeley.
Sharon Reese
Head of Accounting
Leads the Accounting and financial reporting for Health Outlook. CFO Partner at TechCXO with extensive experience in life sciences. Previously Chief Financial Officer and Vice President of Finance & Compliance at AgNovos Bioscience, BioReliance, and United BioSource Corporation. B.S. in Accounting, Penn State University and Certified Public Accountant.
Jason Wang
Chief Medical Scientist
Director of the Center for Policy, Outcomes, and Prevention, and Professor of Pediatrics and Health Policy at Stanford University. Co-chairs the mobile health and other new technologies group at the Stanford Center for Population Health Sciences. B.S. in molecular biology from MIT, M.D. from Harvard Medical School, and Ph.D. in policy analysis from RAND.
Tadd Wessel
Managing Partner, Petrichor Healthcare Capital Management
Mr. Wessel was formerly a Managing Director at OrbiMed Advisors and Vice President at Fortress Investment Group. He sits on numerous boards of directors of life sciences companies as well as the International Centers for Precision Oncology (ICPO) Foundation. A.B. in Biology from Princeton University.
Adam Morgan
Partner at Avego,
CIO of Velan Capital
Career spanning two decades through the healthcare and fundamental asset management. Before Avego he worked at Broadfin Capital, Iguana Healthcare and Pura Vida Investments. Previous role at Cowen and Company. BS in Chemistry from the University of Minnesota, MBA from the Carlson School of Management at the University of Minnesota.
John Rydzewski
Advisor,
Health Markets
Heads the Rand Corporation Heath Advisory Board. Banker at Solomon Partners. Former fund manager and long-time investment banker. Received MBA from Wharton.
Joseph Konowiecki, J.D.
Chairman,
Alignment Health
As General Counsel for PacifiCare, one of the nation's largest health organizations, he was instrumental in closing its $9.2 billion sale to United Health. He is currently Chairman of Alignment Healthcare, a rapidly growing Medicare insurer. He serves on the board of directors for Health Outlook.
Tim Opler, Ph.D.
Co-Founder,
Health Outlook
Partner at Torreya, former professor and entrepreneur. Serves on boards of multiple private companies. Previously at Credit Suisse in healthcare investment banking and at FibroGen in a strategy role. Ph.D., Econ, UCLA.
Andy Dannenberg, M.D.
Former Professor Medicine,
Weill Cornell Medical College
Partner at Emerald Bioventures. Formerly was Professor of Medicine at Weill Cornell Medical College. Author of 200+ scientific publications. Expert on inflammation and cancer. MD Wash U., St. Louis.
Paul Ridker, M.D.
Professor of Medicine,
Harvard University
Dr. Ridker is a cardiovascular epidemiologist and biomedical researcher whose research has provided proof-of-principle for the inflammation hypothesis of atherosclerosis and the first proven anti-inflammatory treatment for coronary artery disease.
Richard Ulevitch, Ph.D.
Dept. Immunology,
Scripps Research Institute
Richard Ulevitch is professor of immunology and Chairman Emeritus of the Department of Immunology at The Scripps Research Institute. His career is marked by a number of seminal scientific discoveries in the field of innate immunity. He has a strong ongoing interest in implications of proteomics for science and medicine. He received a Ph.D. in Immunology from the University of Pennsylvania.
David Shulkin, M.D.
Former Secretary,
Veterans Administration
Dr. Shulkin is an American physician and former U.S. Secretary of Veterans Affairs. Shulkin was also CEO of Beth Israel Medical Center and was president of Morristown Medical Center. He was the first CMO of the University of Pennsylvania Hospital.
Mark Simon
Co-Founder and Advisor, Torreya
Mark Simon is a partner at Torreya Partners, which he co-founded in 2007. He brings over 20 years of experience in advising biotech companies. He is active on numerous boards including that for the Alliance for Aging Research. Before Torreya, Simon in investment banking at Citigroup and Robertson Stephens. Mark received an MBA from Harvard Business School.
Ravi J. Patel, D.O.
Board Certified Emergency Medicine
Ravi Patel is a Board Certified Emergency Physician. He completed his medical school at the West Virginia School of Osteopathic Medicine and completed his residency at the University of Missouri-Kansas City where he served as chief resident. Dr. Patel has become passionate about digital health and using health informatics to solve complex logistical and analytical problems.
Dan Lewis
Board Member, Lobesity
Accomplished C-suite executive across multiple industries. Recently, worked in healthcare as the COO of a $1.5B hospital system and in biotech as the CEO of Lobesity, a start-up company dedicated to the treatment of obesity. Successfully led the exit in 2021 and remains a Board Member. Currently, advises other start-ups in the health tech sector. Received a BA degree from Kent State University and an MA from the University of Akron.